Capricor Therapeutics (CAPR) Net Cash Flow (2010 - 2026)

Capricor Therapeutics' Net Cash Flow history runs 17 years deep, the most recent figure standing at -$182.4 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 1141.99% year-over-year to -$182.4 million; the TTM figure through Mar 2026 stood at $76.6 million (up 239.36% YoY), while the FY2025 annual figure was $276.6 million, up 8215.36% from the prior year.
• Net Cash Flow was -$182.4 million for Q1 2026 at Capricor Therapeutics, down from $268.3 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $268.3 million in Q4 2025 to a low of -$182.4 million in Q1 2026.
• Historically, Net Cash Flow has averaged $4.1 million across 5 years, with a median of -$768395.0 in 2023.
• The sharpest annual moves came in 2024 and 2026: Net Cash Flow soared 6867.31% in 2024, then tumbled 1141.99% in 2026.
• A 5-year view of Net Cash Flow shows it stood at $1.2 million in 2022, then jumped by 380.01% to $5.7 million in 2023, then sank by 1099.8% to -$57.1 million in 2024, then surged by 570.02% to $268.3 million in 2025, then slumped by 167.98% to -$182.4 million in 2026.
• The last three Net Cash Flow figures came in at -$182.4 million (Q1 2026), $268.3 million (Q4 2025), and -$3.7 million (Q3 2025), per Business Quant data.